Blood–brain barrier structure and function and the challenges for CNS drug delivery
Corresponding Author
N. Joan Abbott
BBB Group, Institute of Pharmaceutical Science, King's College London, 150 Stamford St, London, SE1 9NH UK
Telephone: +44-207-8484016, Fax: +44-207-848 4781, [email protected]
Search for more papers by this authorCorresponding Author
N. Joan Abbott
BBB Group, Institute of Pharmaceutical Science, King's College London, 150 Stamford St, London, SE1 9NH UK
Telephone: +44-207-8484016, Fax: +44-207-848 4781, [email protected]
Search for more papers by this authorCommunicated by: Maurizio Scarpa
Presented at the “Brains for Brain Meeting”, Frankfurt, Germany, 9–11 March 2012
Abstract
The neurons of the central nervous system (CNS) require precise control of their bathing microenvironment for optimal function, and an important element in this control is the blood–brain barrier (BBB). The BBB is formed by the endothelial cells lining the brain microvessels, under the inductive influence of neighbouring cell types within the ‘neurovascular unit’ (NVU) including astrocytes and pericytes. The endothelium forms the major interface between the blood and the CNS, and by a combination of low passive permeability and presence of specific transport systems, enzymes and receptors regulates molecular and cellular traffic across the barrier layer. A number of methods and models are available for examining BBB permeation in vivo and in vitro, and can give valuable information on the mechanisms by which therapeutic agents and constructs permeate, ways to optimize permeation, and implications for drug discovery, delivery and toxicity. For treating lysosomal storage diseases (LSDs), models can be included that mimic aspects of the disease, including genetically-modified animals, and in vitro models can be used to examine the effects of cells of the NVU on the BBB under pathological conditions. For testing CNS drug delivery, several in vitro models now provide reliable prediction of penetration of drugs including large molecules and artificial constructs with promising potential in treating LSDs. For many of these diseases it is still not clear how best to deliver appropriate drugs to the CNS, and a concerted approach using a variety of models and methods can give critical insights and indicate practical solutions.
Conflict of interest
None
References
- Abbott NJ, Bradbury MWB (1992) Comparative physiology of the blood–brain barrier. In: Physiology and pharmacology of the blood–brain barrier (Handbk Exp Pharmacol 103), Heidelberg: Springer, 371–396.
10.1007/978-3-642-76894-1_15 Google Scholar
- Abbott NJ (2004) Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem Int, 45: 545–552, .
- Abbott NJ (2004) Prediction of blood–brain barrier permeation in drug discovery, from in vivo, in vitro and in silico models. Drug Discov Today: Technol, 1: 407–416, .
- Abbott NJ, Friedman A (2012) Overview and introduction: the blood–brain barrier in health and disease. Epilepsia, 53 (Suppl): 1–6.
10.1111/j.1528-1167.2012.03696.x Google Scholar
- Abbott NJ, Rönnbäck L, Hansson E (2006) Astrocyte-endothelial interactions at the blood–brain barrier. Nat Rev Neurosci, 7: 41–53, .
- Abbott NJ, Dolman DE, Patabendige AK (2008) Assays to predict drug permeation across the blood–brain barrier, and distribution to brain. Curr Drug Metab, 9: 901–910, .
- Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ (2010) Structure and function of the blood–brain barrier. Neurobiol Dis, 37: 13–25, .
- Anson DS, McIntyre C, Byers S (2011) Therapies for neurological disease in the mucopolysaccharidoses. Curr Gene Ther, 11: 132–143, .
10.2174/156652311794940791 Google Scholar
- Arfi A, Richard M, Gandolphe C, Bonnefont-Rousselot D, Thérond P, Scherman D (2011) Neuroinflammatory and oxidative stress phenomena in MPS IIIA mouse model: the positive effect of long-term aspirin treatment. Mol Genet Metab, 103: 18–25, .
- Armulik A, Genové G, Mäe M, et al (2010) Pericytes regulate the blood–brain barrier. Nature, 468: 557–561, .
- Armulik A, Genové G, Betsholtz C (2011) Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell, 21: 193–215, .
- Avdeef A (2011) How well can in vitro brain microcapillary endothelial cell models predict rodent in vivo blood–brain barrier permeability?. Eur J Pharm Sci, 43: 109–124, .
- Avdeef A (2012) Absorption and drug development: Solubility, permeability, and charge, 2. Hoboken: Wiley, 698pp.
- Begley DJ, Brightman MW (2003) Structural and functional aspects of the blood–brain barrier. Progr Drug Res, 61: 39–78.
- Begley DJ, Pontikis CC, Scarpa M (2008) Lysosomal storage diseases and the blood–brain barrier. Curr Pharm Des, 14: 1566–1580, .
- Bell RD, Winkler EA, Sagare AP, et al (2010) Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron, 68: 409–427, .
- Bellettato CM, Scarpa M (2010) Pathophysiology of neuropathic lysosomal storage disorders. J Inherit Metab Dis, 33: 347–362, .
- Benarroch EE (2011) Circumventricular organs: receptive and homeostatic functions and clinical implications. Neurology, 77: 1198–1204, .
- Bikadi Z, Hazai I, Malik D, et al (2011) Predicting P-glycoprotein-mediated drug transport based on support vector machine and three-dimensional crystal structure of P-glycoprotein. PLoS One, 6: e25815, .
- Cabrera-Salazar MA, Deriso M, Bercury SD, et al (2012) Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease. PLoS One, 7: e43310, .
- Calias P, Papisov M, Pan J, et al (2012) CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder. PLoS One, 7: e30341, .
- Candela P, Gosselet F, Miller F, et al (2008) Physiological pathway for low-density lipoproteins across the blood–brain barrier: transcytosis through brain capillary endothelial cells in vitro. Endothelium, 15: 254–264, .
- Candela P, Gosselet F, Saint-Pol J, et al (2010) Apical-to-basolateral transport of amyloid-β peptides through blood–brain barrier cells is mediated by the receptor for advanced glycation end-products and is restricted by P-glycoprotein. J Alzheimers Dis, 22: 849–859.
- Carruthers A, DeZutter J, Ganguly A, Devaskar SU (2009) Will the original glucose transporter isoform please stand up!. Am J Physiol Endocrinol Metab, 297: E836–E848, .
- Cecchelli R, Dehouck B, Descamps L, et al (1999) In vitro model for evaluating drug transport across the blood–brain barrier. Adv Drug Deliv Rev, 36: 165–178, .
- Cecchelli R, Berezowski V, Lundquist S, et al (2007) Modelling of the blood–brain barrier in drug discovery and development. Nat Rev Drug Discov, 6: 650–661, .
- Chen YH, Claflin K, Geoghegan JC, Davidson BL (2012) Sialic acid deposition impairs the utility of AAV9, but not peptide-modified AAVs for brain gene therapy in a mouse model of lysosomal storage disease. Mol Ther, 20: 1393–1399, .
- Costantino L, Boraschi D (2012) Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents?. Drug Discov Today, 17: 367–378, .
- Dagenais C, Avdeef A, Tsinman O, Dudley A, Beliveau R (2009) P-glycoprotein deficient mouse in situ blood–brain barrier permeability and its prediction using an in combo PAMPA model. Eur J Pharm Sci, 38: 121–137, .
- Daneman R, Agalliu D, Zhou L, Kuhnert F, Kuo CJ, Barres BA (2009) Wnt/beta-catenin signaling is required for CNS, but not non-CNS, angiogenesis. Proc Natl Acad Sci U S A, 106: 641–646, .
- Daneman R, Zhou L, Kebede AA, Barres BA (2010) Pericytes are required for blood–brain barrier integrity during embryogenesis. Nature, 468: 562–566, .
- Dauchy S, Dutheil F, Weaver RJ, et al (2008) ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood–brain barrier. J Neurochem, 107: 1518–1528, .
- Deli MA, Abrahám CS, Kataoka Y, Niwa M (2005) Permeability studies on in vitro blood–brain barrier models: physiology, pathology, and pharmacology. Cell Mol Neurobiol, 25: 59–127, .
- Descamps L, Dehouck MP, Torpier G, Cecchelli R (1996) Receptor-mediated transcytosis of transferrin through blood–brain barrier endothelial cells. Am J Physiol, 270: H1149–H1158.
- Dickson PI, Chen AH (2011) Intrathecal enzyme replacement therapy for mucopolysaccharidosis I: translating success in animal models to patients. Curr Pharm Biotechnol, 12: 946–955, .
- Dickson P, McEntee M, Vogler C, et al (2007) Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol Genet Metab, 91: 61–68, .
- Dohgu S, Ryerse JS, Robinson SM, Banks WA (2012) Human immunodeficiency virus-1 uses the mannose-6-phosphate receptor to cross the blood–brain barrier. PLoS One, 7: e39565, .
- Dutheil F, Jacob A, Dauchy S (2010) ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders. Expert Opin Drug Metab Toxicol, 6: 1161–1174, .
- Engelhardt B, Ransohoff RM (2012) Capture, crawl, cross: the T cell code to breach the blood–brain barriers. Trends Immunol, 33: 579–589, .
- Farfel-Becker T, Vitner EB, Pressey SN, Eilam R, Cooper JD, Futerman AH (2011) Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease. Hum Mol Genet, 20: 1375–1386, .
- Fillebeen C, Descamps L, Dehouck MP, et al (1999) Receptor-mediated transcytosis of lactoferrin through the blood–brain barrier. J Biol Chem, 274: 7011–7017, .
- Franke H, Galla HJ, Beuckmann CT (1999) An improved low-permeability in vitro-model of the blood–brain barrier: transport studies on retinoids, sucrose, haloperidol, caffeine and mannitol. Brain Res, 818: 65–71, .
- Fu H, Dirosario J, Killedar S, Zaraspe K, McCarty DM (2011) Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood–brain barrier gene delivery. Mol Ther, 19: 1025–1033, .
- Garbuzova-Davis S, Louis MK, Haller EM, Derasari HM, Rawls AE, Sanberg PR (2011) Blood–brain barrier impairment in an animal model of MPS III B. PLoS One, 6: e16601, .
- Garcia MA, Carrasco M, Godoy A, et al (2001) Elevated expression of glucose transporter-1 in hypothalamic ependymal cells not involved in the formation of the brain-cerebrospinal fluid barrier. J Cell Biochem, 80: 491–503, .
- Ghosh C, Puvenna V, Gonzalez-Martinez J, Janigro D, Marchi N (2011) Blood–brain barrier P450 enzymes and multidrug transporters in drug resistance: a synergistic role in neurological diseases. Curr Drug Metab, 12: 742–749, .
- Gleeson MP (2008) Generation of a set of simple, interpretable ADMET rules of thumb. J Med Chem, 51: 817–834, .
- Grubb JH, Vogler C, Levy B, Galvin N, Tan Y, Sly WS (2008) Chemically modified beta-glucuronidase crosses blood–brain barrier and clears neuronal storage in murine mucopolysaccharidosis VII. Proc Natl Acad Sci U S A, 105: 2616–2621, .
- Grubb JH, Vogler C, Sly WS (2010) New strategies for enzyme replacement therapy for lysosomal storage diseases. Rejuvenation Res, 13: 229–236, .
- Guffon N, Bin-Dorel S, Decullier E, Paillet C, Guitton J, Fouilhoux A (2011) Evaluation of miglustat treatment in patients with type III mucopolysaccharidosis: a randomized, double-blind, placebo-controlled study. J Pediatr, 159: 838–844, .
- Hamilton NB, Attwell D, Hall CN (2011) Pericyte-mediated regulation of capillary diameter: a component of neurovascular coupling in health and disease. Front Neuroenergetics, 2: ii5, doi:10.3389/fnene.2010.00005.
- Hammarlund-Udenaes M, Fridén M, Syvänen S, Gupta A (2008) On the rate and extent of drug delivery to the brain. Pharm Res, 25: 1737–1750, .
- Haqqani AS, Stanimirovic DB (2011) Intercellular interactomics of human brain endothelial cells and th17 lymphocytes: a novel strategy for identifying therapeutic targets of CNS inflammation. Cardiovasc Psychiatry Neurol, 2011: 175364.
- Hemsley KM, Hopwood JJ (2010) Lessons learnt from animal models: pathophysiology of neuropathic lysosomal storage disorders. J Inherit Metab Dis, 33: 363–371, .
- Hervé F, Ghinea N, Scherrmann JM (2008) CNS delivery via adsorptive transcytosis. AAPS J, 10: 455–472, .
- Iadecola C, Nedergaard M (2007) Glial regulation of the cerebral microvasculature. Nat Neurosci, 10: 1369–1376, .
- Ishikawa T, Saito H, Hirano H, Inoue Y, Ikegami Y (2012) Human ABC transporter ABCG2 in cancer chemotherapy: drug molecular design to circumvent multidrug resistance. Meth Mol Biol, 910: 267–278, .
10.1007/978-1-61779-965-5_11 Google Scholar
- Jolly RD, Marshall NR, Perrott MR, Dittmer KE, Hemsley KM, Beard H (2011) Intracisternal enzyme replacement therapy in lysosomal storage diseases: routes of absorption into brain. Neuropathol Appl Neurobiol, 37: 414–422, .
- Jones AR, Shusta EV (2007) Blood–brain barrier transport of therapeutics via receptor-mediation. Pharm Res, 24: 1759–1771, .
- Kandel ER, Schwartz J, Jessel T (2000) Principles of neural science, 4. New York: McGraw Hill.
- Katona RL, Sinkó I, Holló G, et al (2008) A combined artificial chromosome-stem cell therapy method in a model experiment aimed at the treatment of Krabbe's disease in the Twitcher mouse. Cell Mol Life Sci, 65: 3830–3838, .
- Killedar S, Dirosario J, Divers E, Popovich PG, McCarty DM, Fu H (2010) Mucopolysaccharidosis IIIB, a lysosomal storage disease, triggers a pathogenic CNS autoimmune response. J Neuroinflammation, 7: 39, .
- Kloska A, Narajczyk M, Jakóbkiewicz-Banecka J, et al (2012) Synthetic genistein derivatives as modulators of glycosaminoglycan storage. J Transl Med, 10: 153, .
10.1186/1479-5876-10-153 Google Scholar
- Koshiba S, An R, Saito H, Wakabayashi K, Tamura A, Ishikawa T (2008) Human ABC transporters ABCG2 (BCRP) and ABCG4. Xenobiotica, 38: 863–888, .
- Kovács R, Papageorgiou I, Heinemann U (2011) Slice cultures as a model to study neurovascular coupling and blood brain barrier in vitro. Cardiovasc Psychiatry Neurol, 2011: 646958.
- Liddelow SA, Temple S, Møllgård K, et al (2012) Molecular characterisation of transport mechanisms at the developing mouse blood-CSF interface: a transcriptome approach. PLoS One, 7: e33554, .
- Lippmann ES, Azarin SM, Kay JE, et al (2012) Derivation of blood–brain barrier endothelial cells from human pluripotent stem cells. Nat Biotechnol, 30: 783–791, .
- Liu M, Hou T, Feng Z, Li Y (2012) The flexibility of P-glycoprotein for its poly-specific drug binding from molecular dynamics simulations. J Biomol Struct Dyn Aug 13. [Epub ahead of print] PubMed PMID: 22888853
- Lockman PR, Mittapalli RK, Taskar KS, et al (2010) Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res, 16: 5664–5678, .
- Lohmann C, Hüwel S, Galla HJ (2002) Predicting blood–brain barrier permeability of drugs: evaluation of different in vitro assays. J Drug Target, 10: 263–276, .
- Lundquist S, Renftel M, Brillault J, Fenart L, Cecchelli R, Dehouck MP (2002) Prediction of drug transport through the blood–brain barrier in vivo: a comparison between two in vitro cell models. Pharm Res, 19: 976–981, .
- Malinowska M, Wilkinson FL, Langford-Smith KJ, et al (2010) Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS One, 5: e14192, .
- Markoutsa E, Pampalakis G, Niarakis A, et al (2011) Uptake and permeability studies of BBB-targeting immunoliposomes using the hCMEC/D3 cell line. Eur J Pharm Biopharm, 77: 265–274, .
- Markoutsa E, Papadia K, Clemente C, Flores O, Antimisiaris SG (2012) Anti-Aβ-MAb and dually decorated nanoliposomes: effect of Aβ1-42 peptides on interaction with hCMEC/D3 cells. Eur J Pharm Biopharm, 81: 49–56, .
- Martin I (2004) Prediction of blood–brain barrier penetration: are we missing the point?. Drug Discov Today, 9: 161–162, .
- Matthes F, Wölte P, Böckenhoff A, et al (2011) Transport of arylsulfatase A across the blood-brain barrier in vitro. J Biol Chem, 286: 17487–17494.
- Matzner U, Herbst E, Hedayati KK, et al (2005) Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy. Hum Mol Genet, 14: 1139–1152, .
- Matzner U, Lüllmann-Rauch R, Stroobants S, et al (2009) Enzyme replacement improves ataxic gait and central nervous system histopathology in a mouse model of metachromatic leukodystrophy. Mol Ther, 17: 600–606, .
- Mayor S, Pagano RE (2007) Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol, 8: 603–612, .
- Miller DS (2010) Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol Sci, 31: 246–254, .
- Muldoon LL, Alvarez JI, Begley DJ, et al (2013) Immunologic privilege in the central nervous system and the blood–brain barrier. J Cereb Blood Flow Metab, 33: 13–21.
- Naik P, Cucullo L (2012) In vitro blood–brain barrier models: current and perspective technologies. J Pharm Sci, 101: 1337–1354, .
- Nakagawa S, Deli MA, Kawaguchi H, et al (2009) A new blood–brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem Int, 54: 253–263, .
- Neuwelt EA (2004) Mechanisms of disease: the blood–brain barrier. Neurosurgery, 54: 131–140, .
- Neuwelt EA, Bauer B, Fahlke C, et al (2011) Engaging neuroscience to advance translational research in brain barrier biology. Nat Rev Neurosci, 12: 169–182, .
- Ni Z, Bikadi Z, Rosenberg MF, Mao Q (2010) Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr Drug Metab, 11: 603–617, .
- Ni Z, Bikadi Z, Shuster DL, Zhao C, Rosenberg MF, Mao Q (2011) Identification of proline residues in or near the transmembrane helices of the human breast cancer resistance protein (BCRP/ABCG2) that are important for transport activity and substrate specificity. Biochemistry, 50: 8057–8066, .
- Ogunshola OO (2011) In vitro modeling of the blood–brain barrier: simplicity versus complexity. Curr Pharm Des, 17: 2755–2761, .
- Ohtsuki S, Terasaki T (2007) Contribution of carrier-mediated transport systems to the blood–brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res, 24: 1745–1758, .
- Pajouhesh H, Lenz GR (2005) Medicinal chemical properties of successful central nervous system drugs. NeuroRx, 2: 541–553, .
- Pardridge WM, Eisenberg J, Cefalu WT (1985) Absence of albumin receptor on brain capillaries in vivo or in vitro. Am J Physiol, 249: E264–E267.
- Parenti G, Pignata C, Vajro P, Salerno M (2013) New strategies for the treatment of lysosomal storage diseases (review). Int J Mol Med, 31: 11–20.
- Patabendige A, Skinner RA, Abbott NJ (2012) Establishment of a simplified in vitro porcine blood–brain barrier model with high transendothelial electrical resistance. Brain Res Jul 10. [Epub ahead of print] PubMed PMID: 22789905
- Platt FM, Jeyakumar M (2008) Substrate reduction therapy. Acta Paediatr Suppl, 97: 88–93, .
- Prinz M, Priller J, Sisodia SS, Ransohoff RM (2011) Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat Neurosci, 14: 1227–1235, .
- Ransohoff RM, Engelhardt B (2012) The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol, 12: 623–635, .
- Redzic Z (2011) Molecular biology of the blood–brain and the blood-cerebrospinal fluid barriers: similarities and differences. Fluids Barriers CNS, 8: 3, .
- Reichel A (2009) Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept. Chem Biodivers, 6: 2030–2049, .
- Reichel A, Begley DJ, Abbott NJ (2003) An overview of in vitro techniques for blood–brain barrier studies. Meth Mol Med, 89: 307–324.
- Reinhardt RR, Bondy CA (1994) Insulin-like growth factors cross the blood–brain barrier. Endocrinology, 135: 1753–1761, .
- Roberts AL, Fletcher JM, Moore L, Byers S (2010) Trans-generational exposure to low levels of rhodamine B does not adversely affect litter size or liver function in murine mucopolysaccharidosis type IIIA. Mol Genet Metab, 101: 208–213, .
- Saha A, Sarkar C, Singh SP, et al (2012) The blood–brain barrier is disrupted in a mouse model of infantile neuronal ceroid lipofuscinosis: amelioration by resveratrol. Hum Mol Genet, 21: 2233–2244, .
- Saunders NR, Liddelow SA, Dziegielewska KM (2012) Barrier mechanisms in the developing brain. Front Pharmacol, 3: 46, .
- Schiffmann R (2010) Therapeutic approaches for neuronopathic lysosomal storage disorders. J Inherit Metab Dis, 33: 373–379, .
- Schultz ML, Tecedor L, Chang M, Davidson BL (2011) Clarifying lysosomal storage diseases. Trends Neurosci, 34: 401–410, .
- Sengillo JD, Winkler EA, Walker CT, Sullivan JS, Johnson M, Zlokovic BV (2013) Deficiency in mural vascular cells coincides with blood–brain barrier disruption in Alzheimer's disease. Brain Pathol, 23: 303–310.
- Shah KK, Yang L, Abbruscato TJ (2012) In vitro models of the blood–brain barrier. Meth Mol Biol, 814: 431–449, .
10.1007/978-1-61779-452-0_29 Google Scholar
- Shawahna R, Uchida Y, Declèves X, et al (2011) and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol Pharm, 8: 1332–1341, .
- Simionescu M, Popov D, Sima A (2009) Endothelial transcytosis in health and disease. Cell Tissue Res, 335: 27–40, .
- Skinner RA, Gibson RM, Rothwell NJ, Pinteaux E, Penny JI (2009) Transport of interleukin-1 across cerebromicrovascular endothelial cells. Br J Pharmacol, 156: 1115–1123, .
- Smith QR (2003) A review of blood–brain barrier transport techniques. Meth Mol Med, 89: 193–208.
- Spencer BJ, Verma IM (2007) Targeted delivery of proteins across the blood–brain barrier. Proc Natl Acad Sci U S A, 104: 7594–7599, .
- Stamatovic SM, Sladojevic N, Keep RF, Andjelkovic AV (2012) Relocalization of junctional adhesion molecule A during inflammatory stimulation of brain endothelial cells. Mol Cell Biol, 32: 3414–3427, .
- Stanimirovic DB, Friedman A (2012) Pathophysiology of the neurovascular unit: disease cause or consequence?. J Cereb Blood Flow Metab, 32: 1207–1221, .
- Stroobants S, Gerlach D, Matthes F, et al (2011) Intracerebroventricular enzyme infusion corrects central nervous system pathology and dysfunction in a mouse model of metachromatic leukodystrophy. Hum Mol Genet, 20: 2760–2769, .
- Thanabalasundaram G, Schneidewind J, Pieper C, Galla HJ (2011) The impact of pericytes on the blood–brain barrier integrity depends critically on the pericyte differentiation stage. Int J Biochem Cell Biol, 43: 1284–1293, .
- Tomanin R, Zanetti A, Zaccariotto E, D'Avanzo F, Bellettato CM, Scarpa M (2012) Gene therapy approaches for lysosomal storage disorders, a good model for the treatment of mendelian diseases. Acta Paediatr, 101: 692–701, .
- Tosi G, Fano RA, Bondioli L, et al (2011) Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood–brain barrier. Nanomedicine (Lond), 6: 423–436, .
- Tsinman O, Tsinman K, Sun N, Avdeef A (2011) Physicochemical selectivity of the BBB microenvironment governing passive diffusion-matching with a porcine brain lipid extract artificial membrane permeability model. Pharm Res, 28: 337–363, .
- Tucker IG, Yang L, Mujoo H (2012) Delivery of drugs to the brain via the blood brain barrier using colloidal carriers. J Microencapsul, 29: 475–486, .
10.3109/02652048.2012.658445 Google Scholar
- Urayama A, Grubb JH, Sly WS, Banks WA (2004) Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood–brain barrier. Proc Natl Acad Sci U S A, 101: 12658–12663, .
- Vandenhaute E, Dehouck L, Boucau MC, et al (2011) Modelling the neurovascular unit and the blood–brain barrier with the unique function of pericytes. Curr Neurovasc Res, 8: 258–269, .
- Vercauteren D, Vandenbroucke RE, Jones AT, et al (2010) The use of inhibitors to study endocytic pathways of gene carriers: optimization and pitfalls. Mol Ther, 18: 561–569, .
- Vezzani A, French J, Bartfai T, Baram TZ (2011) The role of inflammation in epilepsy. Nat Rev Neurol, 7: 31–40, .
- Visigalli I, Delai S, Politi LS, et al (2010) Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Blood, 116: 5130–5139, .
- Vitner EB, Platt FM, Futerman AH (2010) Common and uncommon pathogenic cascades in lysosomal storage diseases. J Biol Chem, 285: 20423–20427, .
- Vitner EB, Farfel-Becker T, Eilam R, Biton I, Futerman AH (2012) Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease. Brain, 135: 1724–1735, .
- Vogler C, Levy B, Grubb JH, et al (2005) Overcoming the blood–brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc Natl Acad Sci U S A, 102: 14777–14782, .
- Wang P, Xue Y, Shang X, Liu Y (2010) Diphtheria toxin mutant CRM197-mediated transcytosis across blood–brain barrier in vitro. Cell Mol Neurobiol, 30: 717–725, .
- Wen CJ, Zhang LW, Al-Suwayeh SA, Yen TC, Fang JY (2012) Theranostic liposomes loaded with quantum dots and apomorphine for brain targeting and bioimaging. Int J Nanomedicine, 7: 1599–1611.
- Wilhelm I, Fazakas C, Krizbai IA (2011) In vitro models of the blood–brain barrier. Acta Neurobiol Exp (Wars), 71: 113–128.
- Winkler EA, Bell RD, Zlokovic BV (2011) Central nervous system pericytes in health and disease. Nat Neurosci, 14: 1398–1405, .
- Winkler EA, Sengillo JD, Bell RD, Wang J, Zlokovic BV (2012) Blood-spinal cord barrier pericyte reductions contribute to increased capillary permeability. J Cereb Blood Flow Metab, 32: 1841–1852, .
- Winkler EA, Sengillo JD, Sullivan JS, Henkel JS, Appel SH, Zlokovic BV (2013) Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol, 125: 111–120, .
- Wittkowski W (1998) Tanycytes and pituicytes: morphological and functional aspects of neuroglial interaction. Microsc Res Tech, 41: 29–42, .
10.1002/(SICI)1097-0029(19980401)41:1<29::AID-JEMT4>3.0.CO;2-P CASPubMedWeb of Science®Google Scholar
- Ylikangas H, Peura L, Malmioja K, et al (2012) Structure-activity relationship study of compounds binding to large amino acid transporter 1 (LAT1) based on pharmacophore modeling and in situ rat brain perfusion. Eur J Pharm Sci, 84: 523–531, doi:10.1016/j.ejps.2012.11.014.
- Zlokovic BV (2005) Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci, 28: 202–208, .
- Zlokovic BV (2010) Neurodegeneration and the neurovascular unit. Nat Med, 16: 1370–1371, .